-
Mashup Score: 14Job descriptions by oncology patient navigator experience - 10 day(s) ago
This article provides guidance and examples for creating patient navigator job descriptions based on levels of expertise that align with the roles and responsibilities detailed in the January 2024 pu…
Categories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial - 10 day(s) ago
In REDUCE, a 4-year randomized trial of dutasteride vs. placebo for prostate cancer prevention among men with an elevated prostate-specific antigen and a negative prestudy biopsy, we found higher Hom…
Categories: General Medicine News, Onc News and JournalsTweet-
Does insulin resistance predict #ProstateCancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial https://t.co/B5lv1bsP0M https://t.co/2ULAmmVfng
-
-
Mashup Score: 50
The cytomorphologic features of thoracic SMARCA4–deficient malignancies are not entirely specific but are distinctive enough to suspect the diagnosis in the appropriate clinical setting. The combinat…
Categories: General Medicine News, Oncologists1Tweet-
💥 New & #OpenAccess: FNA and effusion cytology of thoracic SMARCA4–deficient undifferentiated tumor and SMARCA4-deficient NSCLC: A multi-institutional experience with 27 patients https://t.co/Tqu0XuvXYM #CytoPath @PathPro @SatturwarSwati @smlungpathguy @ZallesNicole https://t.co/WDG82Jc6jg
-
-
Mashup Score: 25Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505 - 10 day(s) ago
Higher chemotherapy dose density is associated with improved overall survival in patients with resectable pancreatic adenocarcinoma receiving perioperative chemotherapy.
Categories: General Medicine News, Oncologists1Tweet-
New & available #OpenAccess | Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505 https://t.co/ewZ67dipkl @SyedAAhmad5 @DavendraSohal @FlavioRochaMD @HH_Oncodr CC: @CathyEngMD @OncoAlert https://t.co/7ZUoTeZzmv
-
-
Mashup Score: 17Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality - 10 day(s) ago
The authors compared the ability of MB PSA, PSA doubling time, and PSA velocity in assessing future risk of lethal prostate cancer. Their findings failed to observe a statistical difference among the…
Categories: General Medicine News, Oncologists1Tweet-
New study from @HenryFordHealth researchers suggests PSA velocity or PSA doubling time were not superior to midlife baseline in assessing the likelihood of developing lethal #ProstateCancer. https://t.co/b5phrB0MTB @DrFAbdollah @OncoAlert @WalterStadler5 #PCSM https://t.co/S5KovayXL8
-
-
Mashup Score: 4
This phase 1 study demonstrated that LY3295668 erbumine, a highly selective, orally bioavailable, and reversible Aurora kinase A inhibitor, both as monotherapy and in combination with standard chemot…
Categories: General Medicine News, Oncologists1Tweet-
New study led by Steven DuBois MD of @DFBC_PedCare evaluates the safety, pharmacokinetics, & antitumor activity of LY3295668 erbumine as monotherapy & combination therapy in children w/ relapsed/refractory neuroblastoma. https://t.co/ACqoLEK4wW @OncoAlert CC: @AbbyRosenbergMD
-
-
Mashup Score: 14
In a retrospective study of patients with Lynch syndrome vs non-Lynch syndrome and microsatellite instability high colorectal cancer, there were no observed differences with immune checkpoint inhibit…
Categories: General Medicine News, Oncologists1Tweet-
Just published from @MayoClinic researchers | Patients with MSI-H CRC treated with ICIs had similar outcomes regardless of germline or somatic MMR mutations, but BRAF V600E mutation was linked to worse prognosis. https://t.co/PmaX19hXqt @GIcancerDoc @Joleen__Hubbard @OncoAlert https://t.co/MJ6eH8Oxgr
-
-
Mashup Score: 7Acute myeloid leukemia management and research in 2025 - 11 day(s) ago
The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic hematopoietic stem cell…
Categories: General Medicine News, Onc News and JournalsTweet-
Acute myeloid leukemia therapy has come a long way since being dominated by cytarabine and anthracyclines. @DrHKantarjian et al review the frontline and later line therapies in AML & discuss important research directions in this review. https://t.co/Vys7JCVfZF @OncoAlert #ASH24 https://t.co/lZIWY7sOps
-
-
Mashup Score: 8Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer - 11 day(s) ago
With complete safety data for 94 patients, the current findings confirm the safety and feasibility of the combination of immune checkpoint inhibitors and pelvic chemoradiotherapy in locally advanced …
Categories: General Medicine News, Oncologists1Tweet-
Final results of this study led by Linda Duska MD, MPH of @uvahealthnew support the safety & feasibility of adding pembrolizumab to pelvic chemoradiation in locally advanced #CervicalCancer, concurrently & sequentially. https://t.co/GvAT1OtkSs @OncoAlert @romano_kara #gyncsm https://t.co/2U5LqqG6iE
-
-
Mashup Score: 12
Increased micronucleus and nuclear budding counts in cytological samples indicate malignancy, and are potential morphological changes that can be added to The Paris System for Reporting Urinary Cytol…
Categories: General Medicine News, Oncologists1Tweet-
🔬 This study aimed to investigate micronuclei and nuclear budding counts in various diagnostic categories of urinary samples. https://t.co/1Ov9quwDMW CC: @MichiyaNishino #CytoPath https://t.co/OnRWsaWYI2
-
New in CANCER: A commentary on job descriptions by oncology patient navigator experience. This resource helps administrators craft standard-aligned roles & supports navigators in career progression. Read more: https://t.co/fyaGKtyIqc @NNRTnews @OncoAlert #PatientNavigation https://t.co/uPpunsM4iS